Insulin-like growth factor-1 promotes cell cycle progression via upregulation of cyclin D1 expression through the phosphatidylinositol 3-kinase/nuclear factor-κB signaling pathway in FRTL thyroid cells

被引:24
|
作者
Ren, Meng [1 ]
Zhong, Xia [1 ]
Ma, Chun-yan [1 ]
Sun, Ying [2 ]
Guan, Qing-bo [1 ]
Cui, Bin [1 ]
Guo, Jun [1 ]
Wang, Hai [1 ]
Gao, Ling [1 ]
Zhao, Jia-jun [1 ]
机构
[1] Shandong Univ, Shandong Prov Hosp, Jinan 250021, Peoples R China
[2] Yantai Yuhuangding Hosp, Dept Endocrinol, Yantai 264000, Peoples R China
基金
中国国家自然科学基金;
关键词
insulin-like growth factor-1; phosphatidylinositol; 3-kinase; nuclear factor-kappa B; cyclin D1; TRANSCRIPTION FACTORS; DEPENDENT KINASES; MAMMALIAN-CELLS; ACTIVATION; APOPTOSIS; DIFFERENTIATION; INHIBITION; TRANSITION; INDUCTION; PI3K/AKT;
D O I
10.1038/aps.2008.8
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Aim: Insulin-like growth factor-1 (IGF-1) is an important hypertrophic and cell cycle progression factor for a number of cell types. It has been proven that IGF-1 is involved in the regulation of thyroid proliferation and cell cycle progression; however, the exact mechanism of this regulation has not been fully elucidated. In the present study, we investigated the effect of IGF-1 on the expression of cyclin D1, an important cell cycle regulatory protein, and a signaling pathway involved in IGF-1's effect on cyclinD1 expression in FRTL thyroid cells. Methods: FRTL thyroid cells were treated with IGF-1 or vector control for 24 h. As appropriate to individual experiments, a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, and/or a nuclear factor-kappa B (NF-kappa B) inhibitor, BAY11-7082, were added 1 h prior to IGF-1 treatment. Western blotting was used to detect cyclin D1 protein expression. Immunofluorescence was performed to analyze the expression of I kappa B alpha, an NF-kappa B inhibitory protein. Cell cycle analysis was performed by fluorescence activated cell sorting (FACS). Results: IGF-1 increased the cyclin D1 expression in thyroid cells. This increase was blocked by pretreatment with LY294002 or BAY11-7082. Further studies showed that IGF-1 specifically induced NF-kappa B activity. Treatment with IGF-1 could accelerate cell cycle progression from G(0)/G(1) to S phase, whereas this progression was inhibited by the presence of LY294002 or BAY11-7082. Conclusion: In summary, the results of the present study show that in FRTL cells, IGF-1 promotes cell cycle progression via an upregulation of cyclin D1 expression, at least partially through the PI3K/NF-kappa B signaling pathway.
引用
收藏
页码:113 / 119
页数:7
相关论文
共 50 条
  • [31] Role of phosphatidylinositol 3-kinase/Akt pathway in angiotensin II and insulin-like growth factor-1 modulation of nitric oxide synthase in vascular smooth muscle cells
    Isenovic, ER
    Meng, Y
    Divald, A
    Milivojevic, N
    Sowers, JR
    ENDOCRINE, 2002, 19 (03) : 287 - 291
  • [32] Microarray analysis of thyroid stimulating hormone, insulin-like growth factor-1, and insulin-induced gene expression in FRTL-5 thyroid cells
    Lee, You Jin
    Park, Do Joon
    Shin, Chan Soo
    Park, Kyong Soo
    Kim, Seong Yeon
    Lee, Hong Kyu
    Park, Young Joo
    Cho, Bo Youn
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2007, 22 (05) : 883 - 890
  • [33] L-Ascorbic acid 2-phosphate promotes elongation of hair shafts via the secretion of insulin-like growth factor-1 from dermal papilla cells through phosphatidylinositol 3-kinase
    Kwack, M. H.
    Shin, S. H.
    Kim, S. R.
    Im, S. U.
    Han, I. S.
    Kim, M. K.
    Kim, J. C.
    Sung, Y. K.
    BRITISH JOURNAL OF DERMATOLOGY, 2009, 160 (06) : 1157 - 1162
  • [34] Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of β1-integrin and phosphatidylinositol 3′-kinase/AKT signaling
    Tai, YT
    Podar, K
    Catley, L
    Tseng, YH
    Akiyama, M
    Shringarpure, R
    Burger, R
    Hideshima, T
    Chauhan, D
    Mitsiades, N
    Richardson, P
    Munshi, NC
    Kahn, CR
    Mitsiades, C
    Anderson, KC
    CANCER RESEARCH, 2003, 63 (18) : 5850 - 5858
  • [35] Insulin-like growth factor-1-induced phosphorylation of transcription factor FKHRL1 is mediated by phosphatidylinositol 3-kinase/Akt kinase and role of this pathway in insulin-like growth factor-1-induced survival of cultured hippocampal neurons
    Zheng, WH
    Kar, S
    Quirion, R
    MOLECULAR PHARMACOLOGY, 2002, 62 (02) : 225 - 233
  • [36] Tumor necrosis factor-α regulates insulin-like growth factor-1 and insulin-like growth factor binding protein-3 expression in vascular smooth muscle
    Anwar, A
    Zahid, AA
    Scheidegger, KJ
    Brink, M
    Delafontaine, P
    CIRCULATION, 2002, 105 (10) : 1220 - 1225
  • [37] Tanshinone I inhibits vascular smooth muscle cell proliferation by targeting insulin-like growth factor-1 receptor/phosphatidylinositol-3-kinase signaling pathway
    Wu, Yu-ting
    Bi, Yi-Ming
    Tan, Zhang-Bin
    Xie, Ling-Peng
    Xu, Hong-Lin
    Fan, Hui-Jie
    Chen, Hong-Mei
    Li, Jun
    Liu, Bin
    Zhou, Ying-Chun
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 853 : 93 - 102
  • [38] Transforming growth factor-β stimulates cyclin D1 expression through activation of β-catenin signaling in chondrocytes
    Li, Tian-Fang
    Chen, Di
    Wu, Qiuqian
    Chen, Mo
    Sheu, Tzong-Jen
    Schwarz, Edward M.
    Drissi, Hicham
    Zuscik, Michael
    O'Keefe, Regis J.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (30) : 21296 - 21304
  • [39] Distinct modes of activation of phosphatidylinositol 3-kinase in response to cyclic adenosine 3′, 5′-monophosphate or insulin-like growth factor I play different roles in regulation of cyclin D1 and p27Kip1 in FRTL-5 cells
    Fukushima, Toshiaki
    Nedachi, Taku
    Akizawa, Hidenori
    Akahori, Masakazu
    Hakuno, Fumihiko
    Takahashi, Shin-Ichiro
    ENDOCRINOLOGY, 2008, 149 (07) : 3729 - 3742
  • [40] Insulin-like growth factor 1/insulin-like growth factor 1 receptor signaling protects against cell apoptosis through the PI3K/AKT pathway in glioblastoma cells
    Zhang, Mingshi
    Liu, Jinrui
    Li, Mingjun
    Zhang, Shihua
    Lu, Yanmei
    Liang, Yanqiu
    Zhao, Kai
    Li, Yingfu
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2018, 16 (02) : 1477 - 1482